News & Events
Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs); and Insight Genetics, a leading molecular diagnostic assay development company, today announced their collaboration to generate an enhanced diagnostic for the expression and mutation of ALK, a major therapeutic target in the treatment of non-small cell lung cancer.
Nashville Medical News profiles the progress of Insight Genetics following recent announcements pertaining to the continued globalization of its products. In addition to continuing its work with QIAGEN to expand access to reliable and efficient tests to identify cancer-causing mutations of anaplastic lymphoma kinase (ALK) in lung cancer, the Insight Genetics team is currently developing a test to expose a biomarker for triple negative breast cancer.
“We are delighted that NCI continues to recognize our company’s leadership in developing diagnostics that enable the prescription of targeted cancer therapies,” said Insight President and COO Christopher Callaghan.
The contracts are the third and fourth awards the company has received from the National Cancer Institute since 2010.
NEW YORK (GenomeWeb News) – Molecular diagnostics company Insight Genetics said on Monday it has been awarded two SBIR contracts from the National Cancer Institute to develop companion diagnostic tests aimed at lung cancer. The contracts, which total about $1.7 million, will go toward developing tests to identify and characterize specific genetic mutations in lung cancer patients. The tests would help physicians decide which therapies are best suited for individual patients.